An inhibitory effect of TZP-4238 on the growth of androgen-sensitive rat prostatic tumor (Dunning R3327).
An inhibitory effect of TZP-4238, a newly synthesized antiandrogen, on the growth of Dunning R3327 rat prostatic tumor was studied and compared with that of chlormadinone acetate (CMA). TZP-4238 markedly suppressed the growth of R3327 tumor. The inhibitory effect of TZP-4238 on the tumor was more potent than that on the prostate. While the inhibitory effect of TZP-4238 on the weight of the ventral prostate was about 6 times as great as that of CMA, the suppressive effect of TZP-4238 on tumor weight was about 40 times as great as that of CMA. Serum levels of testosterone and dihydrotestosterone showed no obvious changes after the administration of either TZP-4238 or CMA. The inhibitory effect of TZP-4238 on the growth of R3327 tumor indicated the application of the compound to human prostatic cancer.
Ichikawa
T
T
Department of Urology, School of Medicine, Chiba University, Japan.
Akimoto
S
S
Shimazaki
J
J
D000284:Administration, Oral; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000728:Androgens / Q000378:metabolism*; D000818:Animals; D002715:Chlormadinone Acetate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013196:Dihydrotestosterone / Q000097:blood; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009919:Orchiectomy; D009929:Organ Size / Q000187:drug effects; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D013737:Testis / Q000187:drug effects / Q000473:pathology; D013739:Testosterone / Q000097:blood
D000726:Androgen Antagonists; D000728:Androgens; D013196:Dihydrotestosterone; D002715:Chlormadinone Acetate; D013739:Testosterone; C069297:osaterone acetate